Treatment of allergic reactions to peanut in recent versus initial reaction
- PDF / 192,624 Bytes
- 2 Pages / 595.276 x 793.701 pts Page_size
- 14 Downloads / 170 Views
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
POSTER PRESENTATION
Open Access
Treatment of allergic reactions to peanut in recent versus initial reaction Moshe Ben-Shoshan1*, Luu Nha Nguyen2, Reza Alizadehfar1, Lianne Soller2, Joe Fragapane2, Lawrence Joseph2,3, Yvan St Pierre2, Laurie Harada4, Carole Fortin5, Mary Allen6, Ann Clarke2,7 From AllerGen NCE Inc.’s Fifth Annual Research Conference: Innovation from Cell to Society Québec City, QC, Canada. 7-9 February 2010 Background Although studies suggest underuse of epinephrine in food related allergic reactions, it is not clear whether treatment may differ over time in those who have already had an allergic reaction. We sought to characterize treatment of the most recent allergic reaction to peanut versus the initial allergic reaction.
Materials and methods Individuals with an allergist-confirmed peanut allergy were recruited from the Montreal Children’s Hospital and Canadian food allergy advocacy organizations. Data were collected on initial allergic reactions to peanut and most recent reaction to peanut during the year prior to study entry.
Table 1 Epinephrine +/- other medications
Other medications (excluding epinephrine) eg: antihistamines
None
Initial reactions, % (95% CI)
8.9% (5.2, 14)
35.6% (28.6, 43)
55.6% (48, 62.9)
Mild
0.0% (0, 6.4)
28.6% (17.3, 42.2)
71.4% (57.8, 82.7)
Moderate
7.7% (3.1, 15.2)
37.4% (27.4, 48.1)
54.9% (44.2, 65.4)
Severe
27.3% (13.3, 45.5)
42.4% (25.5, 60.8)
30.3% (15.6, 48.7)
Treated only outside HCF
0.0% (0, 9.3)
100.0% (90.7, 100)
Treated only in HCF
44.8% (26.4, 64.3)
55.2% (35.7, 73.6)
Treated outside and in HCF
40% (5.3, 85.3)
60% (14.7, 94.7)
Location unknown
12.5% (0.3, 52.7)
87.5% (47.3, 99.7)
Most recent reactions % (95% 17.2% (12, 23.5) CI)
62.2% (54.7, 69.3)
20.6% (14.9, 27.2)
Mild
5.7% (1.2, 15.7)
64.2% (49.8, 76.9)
30.2% (18.3, 44.3)
Moderate
16.5% (9.7, 25.4)
63.9% (53.5, 73.4)
19.6% (12.2, 28.9) 6.7% (0.8, 22.1)
Severe
40% (22.7, 59.4)
53.3% (34.3, 71.7)
Treated only outside HCF Treated only in HCF
8.8% (3.9, 16.6) 20% (2.5, 55.6)
91.2% (83.4, 96.1) 80% (44.4, 97.5)
Treated outside and in HCF
64% (42.5, 82)
36% (18, 57.5)
Location unknown
29.4% (10.3, 56)
70.6% (44, 89.7)
CI, Confidence interval; HCF, Health Care facility
1
Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Center, Montreal, Canada Full list of author information is available at the end of the article
© 2010 Ben-Shoshan et al; licensee BioMed Central Ltd.
Ben-Shoshan et al. Allergy, Asthma & Clinical Immunology 2010, 6(Suppl 3):P29 http://www.aacijournal.com/content/6/S3/P29
Page 2 of 2
Results See Table 1 Among 180 individuals reporting both an initial allergic reaction and a recent allergic reaction to peanut, epinephrine was administered in 8.9% (95% CI, 5.2-14.0%) and 17.2% (95% CI, 12.0-23.5%) respectively. Treatments excluding epinephrine were given in 35.6% (95% CI, 28.6-43.0%) of initial reactions and in 62.2% (95% CI, 54.7-69.3%) of
Data Loading...
